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Abstract
Background: Fabry disease (FD) is a genetic disorder caused by a deficiency in the enzyme alpha-galactosidase A,
leading to an accumulation of glycosphingolipids in tissues across the body. Cardiac disease is the leading cause of
morbidity and mortality. Advanced disease, characterised by extensive left ventricular hypertrophy, ventricular
dysfunction and fibrosis, is known to be associated with an increase in arrhythmia. Data identifying risk factors for
arrhythmia are limited, and no Fabry-specific risk stratification tool is available to select those who may benefit from
initiation of medical or device therapy (implantable cardiac defibrillators). Current monitoring strategies have a
limited diagnostic yield, and implantable loop recorders (ILRs) have the potential to change treatment and clinical
outcomes.
Aim: The aim of this study is to determine whether ILRs can (1) improve arrhythmia detection in FD and (2) identify
risk predictors of arrhythmia.
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Methods: A prospective, 5-year, open-label, international, multi-centre randomised controlled trial of a minimum of
164 participants with genetically or enzymatically confirmed FD (or both) who have evidence of cardiac disease will be
recruited from five centres: Queen Elizabeth Hospital, Birmingham, UK; Salford Royal Hospital, Salford, UK; Royal Free
Hospital, London, UK; Addenbrookes Hospital, Cambridge, UK; and Westmead Hospital, Sydney, Australia. Participants
will be block-randomised (1:1) to two study arms for cardiac monitoring (i) control arm: standard of care with annual
24 h or 5-day Holter monitor or (ii) treatment arm: continuous cardiac monitoring with ILR implantation plus standard
of care. Participants will undergo multiple investigations—blood/urine biomarkers, 12-lead and advanced
electrocardiogram (ECG) recording, echocardiography and cardiovascular magnetic resonance (CMR) imaging—at
baseline and 6–12 monthly follow-up visits. The primary endpoint is identification of arrhythmia requiring initiation or
alteration in therapy. Secondary outcome measures include characterising the risk factors associated with arrhythmia
and outcome data in the form of imaging, ECG and blood biomarkers.
Discussion: This is the first study evaluating arrhythmia burden and the use of ILR across the spectrum of risk profiles
in Fabry cardiomyopathy. This will enable detailed characterisation of arrhythmic risk predictors in FD and ultimately
support formulation of Fabry-specific guidance in this high-risk population.
Trial registration: ClinicalTrials.gov (NCT03305250). Registered on 9 October 2017.
Keywords: Fabry, Arrhythmia, ILR, Cardiomyopathy
Background
Fabry disease (FD) is an X-linked lysosomal storage
disorder in which a deficiency in the enzyme alpha-
galactosidase A [1] leads to a progressive accumula-
tion of glycosphingolipids such as globotriaosylcera-
mide (Gb3) and globotriaosylsphingosine (lyso-Gb3)
in tissues across the body [2]. Cellular changes within
the tissue microenvironment lead to extensive cardio-
vascular, neurological and renal dysfunction. Clinical
presentation can be extremely variable [3] and devel-
opments in therapy have changed the natural progres-
sion of FD, such that cardiac disease has surpassed
renal involvement as the leading cause of morbidity
and mortality [4]. Cardiovascular involvement is charac-
terised by progressive glycosphingolipid storage, inflam-
mation, left ventricular hypertrophy (LVH), fibrosis,
arrhythmia, congestive cardiac failure and sudden death
[5]. Although a significant proportion of cardiovascular
deaths are ascribed to ‘sudden cardiac events’ and symp-
tomssuchaspalpitationsandsyncopearealmostuniversal,
very little is known regarding the true frequency of
arrhythmia. Registry data have suggested that the rate of
atrial arrhythmia could be as high as 13% [6]. However, the
incidence of ventricular arrhythmia varies widely (5% to
30%) [6].Advancedcardiacdisease characterisedbyexten-
sive LVH, ventricular dysfunction and fibrosis is known to
beassociatedwith an increase in arrhythmianeeding inter-
vention. This includes bradyarrhythmia requiring a per-
manent pacemaker (PPM), ventricular arrhythmia
requiring an implantable cardiac defibrillator (ICD) and
atrial fibrillation (AF) requiring anticoagulation [7]. Lim-
ited data have identified LVH, the presence of late gadolin-
ium enhancement (LGE) left atrial (LA) dilatation, a QRS
durationofmorethan 120 msandanelevatedMainzSever-
ity Score Index (MSSI) as potential arrhythmic risk factors.
However, there is noFabry-specific risk calculator to select
those who might benefit most from therapeutic interven-
tions (such as ICDs) as there are for conditions such as
hypertrophic cardiomyopathy (HCM) [8]. Novel electrical
and blood biomarkers have also recently emerged as poten-
tial predictors of atrial and ventricular arrhythmia. Advances
in technology have enabled computerised electrocardiogram
(ECG) analysis using advanced signal averaging, vectorcar-
diographic reconstruction, singular value decomposition of
QRS and T wave complexity, frequency content analysis,
and beat-to-beat variability—collectively known as advanced
ECG (A-ECG). These A-ECG measures can be applied
retrospectively to digital files of clinically acquired ECGs,
and outcome variables identified as potential arrhythmic
risk markers [9–11]. These markers have a higher sensitivity
and specificity than conventional ECG criteria in prediction
of arrhythmic risk and assessment of conditions such as
LVH and HCM [12, 13]. Cardiac involvement is a major de-
terminant of morbidity and mortality in FD. ECG changes
do not always reflect the extent of cardiac disease, making
assessment with conventional ECG limited [14, 15]. Thus,
detailed analysis of surface ECG markers through A-ECG
could be a powerful tool not only to assess risk of
arrhythmia but potentially to track cardiac pathology in FD.
Local myocardial inflammation has also been shown to
alter electrophysiological properties and contribute to the
arrhythmic vulnerability of cardiac tissue. Specific inflam-
matory biomarkers, such as interleukin-6 (IL-6) and high-
sensitivity C-reactive protein (hs-CRP), have both been
considered potential contributors to the pathophysiological
mechanisms leading to the development of malignant
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ventricular arrhythmia and atrial arrhythmias, such as AF
[16, 17]. Although there are no data on the role of IL-6 or
hs-CRP in predicting arrhythmia in FD, the presence of scar
identified by LGE on cardiovascular magnetic resonance
(CMR) is known to be a risk factor and these lesions in
some patients with FD have been linked to chronic inflam-
mation [18]. As such, their evaluation may provide crucial
information on the potential biochemical mechanisms
underlying arrhythmia generation.
Current monitoring strategies for arrhythmia are limited
to a 12-lead ECG at clinic visits, annual 24-h Holter moni-
toring, and response to a clinical event. However, a signifi-
cant difficulty in clinical management is that, owing to the
frequent nature of palpitations in patients with FD, symp-
tomatic status loses specificity for identifying arrhythmia.
Implantable loop recorders (ILRs) are small and subcuta-
neously inserted devices that enable continuous cardiac
monitoring over the course of a 3-year period. These de-
vices have the potential to modify care and outcomes by
providing definite evidence of arrhythmia and to provide
greater accuracy (due to length of recording) and earlier
detection with remote/home monitoring, particularly in
asymptomatic individuals. Although ILRs do not carry the
same risk as other implanted devices, they are still invasive
and have relatively high cost, so their use needs to be justi-
fied in the current healthcare climate.
Methods
Design
This is a prospective, 5-year, open-label, international,
multi-centre randomised controlled trial to evaluate the
role of ILR in modifying therapy for arrhythmia in FD.
Adults with genetic or enzymatic confirmation of FD who
have evidence of cardiac involvement will be recruited
from five centres: (1) Queen Elizabeth Hospital, Birming-
ham, UK; (2) Salford Royal Hospital, Salford, UK; (3)
Royal Free Hospital, London, UK; (4) Addenbrookes Hos-
pital, Cambridge, UK; and (5) Westmead Hospital, Sydney,
Australia. Participants will be randomly assigned to one of
two study arms for cardiac monitoring: (i) standard of care
using annual 24-h/5-day ECG monitoring according to
local practice or (ii) continuous cardiac monitoring with
ILR implantation plus standard of care. A summary of the
trial design is shown in Fig. 1.
Fig. 1 Study timeline. A minimum of 164 participants will undergo baseline investigation and randomisation to standard care with annual Holter
monitoring or to intervention with an implantable loop recorder device for continued electrocardiogram (ECG) monitoring. All participants will be
followed up at 12 monthly intervals (centre-dependent) for the entire 36-month study period, with investigations repeated at each time-point.
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Null hypothesis
There will be no difference in the identification of clinic-
ally significant arrhythmia that requires treatment modi-
fication between patients following standard care alone
compared with those following standard care with the
addition of ILR monitoring.
Study aims
This trial will compare the rate of clinically significant
arrhythmia requiring intervention identified between the
two surveillance modalities. This information will be
correlated with cardiac investigations performed at inter-
vals (details described below) and thus the study aims
are the following:
1) Identify the true arrhythmic burden in FD.
2) Demonstrate the clinical benefit of ILR in
modifying treatment.
3) Provide detailed data regarding specific risk factors
predisposing to arrhythmic events.
This study will identify the predictive power of both
traditional (LGE, QRS duration, atrial size, and left ven-
tricular (LV) ejection fraction) and novel (troponin, pro-
brain natriuretic peptide (pro-BNP), lyso-Gb3, T1 and T2
mapping, and A-ECG analysis) biomarkers. This will pro-
vide greater clarity on the risk of sudden cardiac death
(SCD) and ultimately guide the formulation of a FD-
specific risk stratification tool for primary prevention.
Participants
Participants will be recruited from Fabry clinics over a
12- to 18-month recruitment period.
Inclusion criteria:
 Adults older than 18 years of age with confirmed FD
(genotypically with a homozygous or heterozygous
Fabry-specific mutation and/or enzymatically de-
fined by absent or reduced alpha-galactosidase A)
 Evidence of cardiac involvement from FD, including
at least one of the following:
Any ECG abnormality associated with FD
(Table 1)
Low T1 on CMR imaging (below centre-
specific normal range according to sex)
LVH on transthoracic echocardiogram or CMR
(defined as maximum wall thickness (MWT) of
more than 12 mm)
Exclusion criteria:
 Patients with an existing cardiac device (PPM, ICD,
cardiac resynchronisation therapy (CRT) or ILR)
 Known dual pathology:
Coronary artery disease (positive non-invasive
imaging, confirmed myocardial infarction, previ-
ous percutaneous or surgical revascularisation).
Patients more than 40 years old with symptoms
that could be from coronary artery disease will
have this excluded.
Cardiomyopathy disease causing mutation (e.g.,
SCN5 and MYBPC3).
The following features have been linked to an in-
crease in the risk of cardiac arrhythmia and SCD [7].
The study population will be enriched with these
arrhythmic risk factors:
 LVH:
Elevated indexed LV mass (greater than two
standard deviations above age, sex and body
surface area indexed measured on steady-state free
precession cine imaging CMR)
MWT of more than 12 mm
 LA dilatation on two-dimensional (2D) transthoracic
echocardiography:
M-mode measurement of more than 40 mm or
biplane volume of more than 34 mL
 Elevated biomarkers (high-sensitivity troponin T or I
above local reference value)
 QRS duration of more than 120 ms on standard
ECG
 Presence of LGE on CMR
 MSSI of more than 20 [19].
Randomisation
A minimum of 164 participants will be recruited and ran-
domly assigned to either the control group receiving
standard of care or the intervention group who will have
continuous cardiac monitoring with an ILR plus standard
of care. A block randomisation process will be performed
by an independent statistician in a 1:1 ratio (Fig. 2). Allo-
cation tables will be imported to the Research Electronic
Data Capture (REDCap) web application software hosted
by the National Hospital for Neurology and Neurosurgery
(London). REDCap is a secure web-based electronic soft-
ware used to facilitate data capture for research studies
[20]. All clinical data collected will be entered directly into
the REDCap case report forms. Sham devices will not be
Table 1 Electrocardiogram (ECG) abnormalities associated with
Fabry disease
ECG abnormality
Short or prolonged PR interval (<120ms or >200 ms)
QRS duration > 120ms
T-wave inversion in at least two contiguous leads
Prolonged QTc
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used in the control group; thus, it will not be possible to
blind clinicians, investigators or patients.
Assessment and follow-up
Following screening assessment for eligibility, all patients
will undergo study entry investigations at their baseline
visit. Subsequent follow-up will occur for 3 years at 6–12
monthly intervals, although recruiting centres have the
option to review patients more frequently depending on
clinical need. All study procedures will be repeated at
follow-up visits. Figure 3 summarises the follow-up period
and clinical procedures that will be undertaken at each
time point. The investigations listed below will be carried
out on the whole study population:
1. Blood and urine analysis
Routine biochemical and haematological parameters, in-
cluding plasma lipids, thyroid function, vitamin D level,
high-sensitivity troponin T or I (site-dependent) and N-
terminal pro brain natriuretic peptide (NT-proBNP), will
be analysed. Additional biomarker analysis will include hs-
CRP and IL-6. Urine samples will be collected for analysis
of albumin-creatinine ratio.
2. Echocardiography
A detailed transthoracic echocardiogram will be per-
formed at each centre by an accredited echocardiographer
in accordance with the British Society of Echocardiography
Minimum Dataset for a Standard Transthoracic Echocar-
diogram [21]. Analysis will be performed locally at each
centre, and ventricular dimensions, wall thickness, chamber
volumes and cardiac output will be evaluated by using
standard guidance [21, 22]. Left ventricular diastolic func-
tion will be evaluated at rest by using standard guidance.
This will include measurement of peak early diastolic (e′)
mitral annular velocities at the septal and lateral walls by
using pulsed wave tissue Doppler in end-expiration, mitral
valve inflow early (E wave) and atrial (A wave) filling vel-
ocity, and atrial volumes measured on 2D from the apical
four-chamber and modified apical two-chamber views [23].
Global longitudinal strain will be measured by speckle-
tracking analysis of 2D images acquired at end-expiration
in the apical four-, two- and three-chamber views in ac-
cordance with current guidance [24].
3. Cardiovascular magnetic resonance imaging
Participants will undergo CMR imaging as part of the re-
search study or as clinically indicated. These will occur at
Birmingham (UK), Barts Heart Centre, Manchester Royal
Infirmary, Addenbrookes Hospital and Royal North Shore
Fig. 2 Block randomisation process. The high-risk features include LVH (MWT > 12mm or elevated LVMi greater than two SD), LA dilatation (M-
mode measurement > 40 mm or biplane volume > 34mL on echo), elevated troponin (above centre specific reference ranges), prolonged QRS
duration > 120ms, presence of LGE on CMR imaging, a MSSI greater than 20. *There will be a variable number of patients from each high-risk
feature group to ensure a variable risk profile within the study cohort (zero risk factors – 20 participants, one risk factor – 40 participants, two risk
factors – 40 participants, three risk factors – 40 participants, four or five risk factors – 24 participants. Abbreviations: CMR cardiac magnetic
resonance imaging, ECG electrocardiogram, ILR implantable loop recorder, LA left atrium, LGE late gadolinium enhancement, LVH left ventricular
hypertrophy, LVMi indexed left ventricular mass, MSSI Mainz severity score index; MWT maximum wall thickness, SD standard deviation, TTE
transthoracic echocardiography.
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Hospital (Sydney, Australia). A 1.5-Tesla MR system
(Avanto (UK), Aera (Australia), Siemens Healthcare, Er-
langen, Germany) and a standard protocol including LV
cines in short axis (SAX), four-chamber, two-chamber and
three-chamber views (ECG R wave gated steady-state free
precession imaging) will be used. Native T1-mapping will
be performed before and after contrast administration by
using a Modified Look-Locker Inversion (MOLLI) recovery
sequence (8-mm slice with a 192 read-out matrix, 6/8
phase partial Fourier with 81% phase resolution, repetition
time 2.4ms, echo time 1.01ms, 11 phases; 3, 3, 5 scheme).
The resulting pixel-by-pixel T1 colour map will be dis-
played by using a customised 12-bit lookup table, where
normal myocardium will be defined as purple, increasing
T1 as pink/red, and decreasing T1 as dark blue. T2 colour
maps will be similarly formed, and increasing T2 will be
shown as orange/yellow. LGE imaging will be performed by
using phase-sensitive inversion recovery (bolus administra-
tion of gadolinium based contrast 0.1mmol/kg body
weight) to quantify the location, pattern and extent of LGE.
Image analysis will be performed offline by an accredited
cardiologist or radiologist at each centre by using Cvi42
(Circle Cardiovascular Imaging Inc., version 5.3.4, Calgary,
AB, Canada) and will include assessment of ventricular
mass, volumes, tissue characterisation with T1/T2 mapping
and assessment for the presence of LGE by using method-
ologies previously described [25].
4. 12-lead ECG and advanced ECG analysis
A standard resting 12-lead ECG (for 10 s at 25mm/s and
10mm/mV) will be acquired at annual study visits and
stored digitally in .xml format. Abnormal ECGs will be de-
fined as the following: (1) LVH classified by traditional
Sokolow–Lyon methodology (SV1 + RV5 or RV6 ≥3.5mV)
and by gender-specific Cornell voltage criteria (RaVL +
SV3 ≥2.8mV in males and ≥2.0mV in females); (2) resting
ST depression or T-wave abnormalities; (3) prolonged QTc
(≥440ms in males and ≥460ms in females); (4) prolonged
QRS duration (≥120ms) or the presence of complete bun-
dle branch block or both; (5) prolonged or shortened PR
interval (>200ms or <120ms respectively); and (6) the pres-
ence of ventricular ectopy. In addition, a continuous 5-min
ECG (1000mm/s and 10mm/mV) will be acquired at rest
Fig. 3 Summary demonstrating participant activity for the duration of the study. All study visits will occur during routine clinical follow-up visits
for Fabry disease surveillance, with only two extra hospital visits for screening and implantable loop recorder (ILR) insertion. The shaded columns
represent optional monitoring visits that will be centre-dependent. Adapted from SPIRIT (Standard Protocol Items Recommendations for
Interventional Trials) figure (2013). Abbreviations: CMR cardiac magnetic resonance, ECG electrocardiogram, QOL quality of life.
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in the supine position by using SpaceEKG technology [26]
and stored electronically as an .xml digital file. Subsequent
offline analysis will be performed by using A-ECG software
(Space EKG Technology, advanced electrocardiogram, ver-
sion 4.36) (Additional file 1). All patients will undergo
annual 24-h or 5-day ECG Holter monitoring and
subsequently data will be analysed on Spacelabs soft-
ware (OSI Systems, Spacelabs Healthcare, Snoqualmie,
WA, USA).
The intervention group will undergo additional study
procedures, as listed below:
5. Insertion of ILR
ILR devices (Medtronic UK or Medtronic Australia) will
be implanted in accordance with centre-specific policies. In
the UK centres, the procedure will be performed by the re-
search team using local anaesthetic and will not require
overnight hospital admission or continued monitoring by
the cardiac physiology department. In Australia, the pro-
cedure will occur at Royal North Shore Hospital (Sydney)
as a day-case hospital admission and will be performed by a
member of the research team who is a senior electrophysi-
ology cardiologist (DW).
6. ILR follow-up
All ILRs for participants within the UK will be followed
up using home monitoring (FocusOn, Medtronic and
Fysiologic BV, Amsterdam, The Netherlands). This is a
continuous cardiac monitoring and triage service. Data
will automatically be sent to the research team within the
lead study site (Birmingham), and information will be dis-
seminated to the participating clinical sites if required.
Surveillance of the Australian participants will be carried
out by using remote home monitoring (Medtronic Reveal
LINQ Monitoring Service, Medtronic Australia), and data
transferred to Royal North Shore Hospital where it will be
disseminated to relevant clinical sites if required. Monitor-
ing information will be transferred to the central study site
on the basis of suspected clinical urgency (red: urgent,
within 24 h; amber: less urgent, within 48 h; green: rou-
tine, within weekly reports). Detailed classification of
arrhythmia can be seen in Additional file 2.
7. ILR removal
The device will be removed after 3 years of being in
situ in accordance with centre-specific policy. The ILR
device will also be removed in those reaching a study
primary endpoint requiring implantation of an alterna-
tive cardiac device (PPM, ICD or CRT). These patients
will continue ongoing follow-up with arrhythmia surveil-
lance via their new device.
Outcome measures
Primary endpoints
The primary endpoint of this study will include any clin-
ically significant arrhythmia requiring initiation or modi-
fication of treatment, which includes the following:
 Atrial fibrillation requiring anticoagulation (defined
as an episode of arrhythmia for a duration greater
than 30 s) [27]
 Bradyarrhythmia requiring pacing (this would
include any symptomatic significant AV block and
Mobitz type 2 AV block or complete heart block
irrespective of symptoms) [28]
 Supraventricular arrhythmia requiring drug
treatment or ablation
 Non-sustained ventricular tachyarrhythmia
requiring drug treatment, ICD implantation or
ablation (defined as three or more ventricular beats
at a rate of more than 120 beats per minute for a
duration of less than 30 s) [29, 30].
Secondary outcome measures
Secondary outcome measures will be evaluated provid-
ing detailed information on arrhythmia in FD. These in-
clude the following:
 Quantification of the arrhythmic burden in FD in
those with or without LGE
 Characterise the relationship between arrhythmia
burden and advanced CMR tissue characterisation
techniques (T1 and T2 mapping)
 Assess the value of ECG abnormalities, particularly a
QRS duration greater than 120 ms, in predicting
arrhythmia
 Assess the predictive value of advanced ECG
analysis in arrhythmia
 Evaluate the role of atrial size in burden of AF
 Determine the effect of LVH and LV mass on
arrhythmia burden
 Assess the relationship of MSSI (a severity score
index used in FD) and burden of arrhythmia
 Evaluate the effect of variations in blood biomarkers
(high-sensitivity troponin, lyso-Gb3, hs-CRP and IL-
6) on the development of arrhythmia.
All endpoints will be reviewed and verified by a data
monitoring committee.
Statistical analysis
Sample size calculation
There is a paucity of knowledge about the burden of
arrhythmia in FD; based on the available literature and
our own collective experience, the following conclusion
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can be made about the necessary sample size for this
study.
Existing literature has shown that over a 7-year period
the incidence of arrhythmia in FD patients under standard
follow-up at a specialist centre (with annual ECG record-
ing and symptom driven investigation) is: atrial fibrillation
6%, bradyarrhythmia requiring device implantation 6%
and cardiac event-related death 3% [30]. These were
evenly spread over the 7-year study period with increased
rates in the older age group. Assuming an even spread of
events detectable over the 3 years of our study, we esti-
mate the background detection rate of clinically significant
events in those meeting the inclusion criteria and follow-
ing standard care to be 5%.
In an enriched population with advanced cardiac in-
volvement identified by the presence of LGE and LVH,
undergoing routine annual 24-h Holter monitoring, the
rate of identification of significant arrhythmia and sudden
cardiac death was 24.6% [31]. Despite assuming a lower
event rate in patients meeting the inclusion criteria for
this study, we estimate the detection rate in the study
group with ILRs will be 20% due to more accurate identifi-
cation of all arrhythmia by these devices. With these
values, for a given population proportion of 0.05 versus
0.2, sample sizes 82 and 82 in the intervention and control
study arms, respectively, and an alpha of 0.05 (two-tailed),
the power of the study is 80%. This means that 80% of
studies would be expected to yield a significant effect,
rejecting the null hypothesis that the two populations have
identical event rates requiring intervention.
Planned statistical analysis
Statistical analyses will be carried out by using SPSS 23
(IBM Corporation, Armonk, NY). All continuous variables
will be expressed as mean ± standard deviation, and all
non-continuous data will be expressed as frequencies or
percentages. Normality will be evaluated by using the Sha-
piro–Wilk test. The independent t test will be used to com-
pare parametric data, and the Mann–Whitney U test will
be used for non-parametric data. Chi-squared or Fisher’s
exact tests will be used to compare proportions within two
independent groups. For comparisons of repeated sample
results, repeated measure analysis of variance (ANOVA)
with post-hoc Bonferroni correction will be used. Time-to-
event (survival) analysis will be performed to evaluate the
presence of arrhythmic events during follow-up. Kaplan–
Meier curves will be used to estimate the cumulative prob-
ability of arrhythmic events, and Cox proportional hazards
regression will be used to evaluate the relationship between
predefined covariates and outcome events. A P value of less
than 0.05 will used for statistical significance.
All patients will have a minimum of 18months’ follow-
up for the primary outcome before interim safety analysis,
which will be performed on an intention-to-treat basis.
The relationship between arrhythmic burden and all other
variables will be analysed by using the methods described
above. An alpha spending function method will be used
for the interim analysis, and a critical P value of less than
0.01 will be used to signify statistical significance.
Additional considerations
Adverse events and participant withdrawal
All adverse and serious adverse events (SAEs) will be re-
ported in accordance with standard International Coun-
cil for Harmonisation Good Clinical Practice reporting
guidelines. SAEs will be reported within 24 h of identifi-
cation to the local study investigator and the chair of the
clinical events review committee (CERC). All SAEs will
be reviewed for causality and ongoing management re-
quirements. Any serious concerns identified by the
CERC may result in modification or termination of the
study or participant withdrawal. Complete withdrawal
criteria are listed in Table 2.
Discussion
The use of ILRs for arrhythmia detection in general car-
diology has increased significantly over the last 10 years.
Newer-generation devices are now considerably smaller
and require a minimally invasive procedure for implant-
ation, thus carrying much lower peri-procedural risk.
The diagnostic yield, in general cardiovascular condi-
tions, from ILR devices is much higher than current
standard-of-care ECG monitoring (stand-alone 12-lead
ECG or ambulatory Holter ECG monitoring) [32]. How-
ever, the benefit of ILR in FD is not defined.
FD is a rare genetic condition characterised by multi-
organ involvement, and significant morbidity and mor-
tality occur secondary to cardiovascular involvement. Al-
though SCD remains a significant cause of death, the
total incidence of malignant ventricular arrhythmia is
variably reported in the literature [33, 34], and there is
no clear guidance on treatment. The rarity and complex-
ity of this disease process have led to a paucity of large
randomised clinical trials in this area, and no studies to
date have been able to fully characterise risk predictors
of arrhythmia. One small single-centre study [34] dem-
onstrated the extensive arrhythmic burden in progressive
disease; however, this included only patients with
Table 2 Participant withdrawal criteria
Withdrawal criteria
Participant’s withdrawal of consent
An adverse event (AE) or serious adverse event (SAE) requiring
withdrawal from study (determined by CERC)
Death
Substantial protocol deviation
Investigator or sponsor decision
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advanced Fabry cardiac disease and consequently did
not fully characterise arrhythmic risk across the
spectrum of Fabry cardiomyopathy.
We have also recently shown that the burden of ven-
tricular arrhythmia is much higher than previously
thought. In a multi-centre study of 109 FD patients who
had previously undergone cardiac device implantation,
the incidence of ventricular arrhythmia requiring med-
ical or device therapy was found to be as high as 25.7%
over a 5-year follow-up period [35], thus highlighting
the extent of arrhythmic burden. Additionally, suspected
arrhythmic risk factors, such as LVH, extensive LGE and
prolonged QRS duration, were all found to be highly
prevalent in this cohort. Detailed risk stratification and
direct correlation with arrhythmia across all FD risk sub-
groups are crucial in developing a greater understanding
of those at risk of life-threatening cardiac arrhythmia.
This study will be the first to identify the true
arrhythmic burden in FD and demonstrate the clinical
benefit of ILR in arrhythmia detection. Additionally, it
will characterise arrhythmic risk across a spectrum of
patients with FD by using novel biomarker techniques
and will allow direct correlation of atrial and ventricular
arrhythmia with underlying structural and functional
changes.
Trial status
This study was due to commence recruitment in January
2019 and have a total recruitment period of 18 months.
Additional files
Additional file 1: Advanced electrocardiogram (ECG) parameters
evaluated during study. (DOCX 14 kb)
Additional file 2: Arrhythmia classification guidance for FocusOn home
monitoring system. (DOCX 13 kb)
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